文献速递外周动脉疾病

LIBERTY 360 研究一年结果:外周血管内器械干预的急性和中期临床结局评估

One-Year Results of the LIBERTY 360 Study: Evaluation of Acute and Midterm Clinical Outcomes of Peripheral Endovascular Device Interventions.
PubMed 文献 · J Endovasc Ther · 2019-02-06

LIBERTY 360 是一项前瞻性、观察性、核心实验室评估的多中心研究,纳入 1204 例外周动脉疾病患者,按 Rutherford 分级分层。结果显示各分层 30 天免于主要不良事件率较高,12 个月免于主要截肢率在 RC2、3 为 99.3%,RC4、5 为 96.0%,RC6 为 81.7%,生活质量显著改善。

要点

  • 血管内干预在 RC2、3、RC4、5 和 RC6 患者中均可行,12 个月免于主要截肢率高。
  • 12 个月免于主要不良事件率随 Rutherford 分级升高而降低:RC2、3 为 82.6%,RC4、5 为 73.2%,RC6 为 59.3%。
  • 所有分层的 VascuQol 总分在 12 个月时均显著改善。

核心结论

  • 外周血管内干预是 RC2、3、RC4、5 和 RC6 患者的可行治疗选择,表现为高免于主要截肢率、生活质量和 Rutherford 分级改善。
  • 在 RC6 患者中,原发性非计划截肢通常并非必要。

研究设计与样本

  • LIBERTY 试验(ClinicalTrials.gov 标识符 NCT01855412)为前瞻性、观察性、核心实验室评估的多中心研究。
  • 纳入 1204 例外周动脉疾病接受血管内器械干预的受试者,平均年龄 69.8±10.7 岁,其中男性 770 例。
  • 按 Rutherford 分级分层:间歇性跛行(RC2、3;n=501)、无/轻微组织缺损的严重肢体缺血(RC4、5;n=603)和显著组织缺损(RC6;n=100)。

主要发现

  • 30 天免于主要不良事件率:RC2、3 为 99.2%,RC4、5 为 96.1%,RC6 为 90.8%。
  • 12 个月免于主要不良事件率:RC2、3 为 82.6%,RC4、5 为 73.2%,RC6 为 59.3%。
  • 12 个月免于主要截肢率:RC2、3 为 99.3%,RC4、5 为 96.0%,RC6 为 81.7%。
  • 12 个月 VascuQol 总分:RC2、3 为 5.3,RC4、5 为 5.0,RC6 为 4.8,所有分组所有领域生活质量评分均显著改善。
  • 血运重建成功且所有分组 Rutherford 分级均有改善。

临床怎么用

  • 对于 RC2、3、RC4、5 和 RC6 患者,可考虑外周血管内干预作为可行治疗选择,尤其关注高免于主要截肢率和生活质量改善。
  • 在 RC6 患者中,原发性非计划截肢通常并非必要,应优先考虑血管内干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the 1-year results of a multicenter study of peripheral artery disease (PAD) treatment with a variety of endovascular treatment strategies employed in routine practice. MATERIALS AND METHODS: The LIBERTY trial ( ClinicalTrials.gov identifier NCT01855412) is a prospective, observational, core laboratory-assessed, multicenter study of endovascular device intervention in 1204 subjects (mean age 69.8±10.7 years; 770 men) stratified by Rutherford category (RC): claudicants (RC2,3; n=501) and critical limb ischemia (CLI) with no/minimal tissue loss (RC4,5; n=603) or significant tissue loss (RC6; n=100). Key outcomes included quality of life (QoL) measures (VascuQol and EuroQol) and freedom from major adverse events (MAE), defined as death (within 30 days), major amputation, and target vessel revascularization based on Kaplan-Meier analysis. RESULTS: Successful revascularization was beneficial, with RC improvement noted across all groups. Thirty-day freedom from MAE estimates were high across all groups: 99.2% in RC2,3, 96.1% in RC4,5, and 90.8% in RC6. At 12 months, the freedom from MAE was 82.6% in RC2,3, 73.2% in RC4,5, and 59.3% in RC6 patients. Estimates for freedom from major amputation at 12 months were 99.3%, 96.0%, and 81.7%, respectively. QoL scores improved significantly across all domains in all groups with 12-month VascuQol total scores of 5.3, 5.0, and 4.8 for RC2,3, RC4,5, and RC6, respectively. CONCLUSION: The results indicate that peripheral endovascular intervention is a viable treatment option for RC2,3, RC4,5, and RC6 patients as evidenced by the high freedom from major amputation, as well as the improvement in QoL and the RC at 12 months. Furthermore, primary unplanned amputation is often not necessary in RC6.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Mustapha J, Gray W, Martinsen BJ, et al. One-Year Results of the LIBERTY 360 Study: Evaluation of Acute and Midterm Clinical Outcomes of Peripheral Endovascular Device Interventions. J Endovasc Ther. 2019. PMID: 30722718. doi:10.1177/1526602819827295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。